Development of Validated Analytical and Bioanalytical Methods for Newer Drug Formulations

Most countries face high and increasing rates of cardiovascular disease (CVDs). Cardiovascular diseases are the number one cause of death globally. The variety and scope of cardiovascular drugs have increased immensely in the past few decades and new drugs are being approved annually. The term cardiovascular drug refers to any medication that affects the heart, blood vessels or the circulatory system. These drugs can be used alone or in combination with each other in the treatment of a variety of disease states such as hypertension, acute coronary syndromes, congestive heart failure (CHF), arrhythmias and dyslipidemias. This thesis deals with the development of validated analytical and bioanalytical methods for the determination of newer cardio vascular drugs in combination form in formulations and biological fluids. An attempt has been made to develop validated analytical and bioanalytical methods for the determination of newer cardio vascular drugs in combination form from formulations and biological fluids. The analytical and bioanalytical methods were validated according to International Conference on Harmonization guidelines for validation of analytical procedures and US Food and Drug Administration bioanalytical method validation guidelines respectively. A comparison of analytical and bioanalytical methods developed in this thesis are shown in tables 8.74-8.76